Home > Analyse
Actualite financiere : Actualite bourse

Novartis: submits additional drug application for Kymriah.

(CercleFinance.com) - Novartis has said that it has submitted a supplemental biologics license application to the US FDA for Kymriah for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

If approved, this would be the second indication for Kymriah, that has already been approved for patients of up to 25 years old with B-cell precursor acute lymphoblastic leukemia.

A novel immunocellular therapy known as "CAR-T," Kymriah uses a patient's own T cells to fight cancer.

Copyright (c) 2017 CercleFinance.com. All rights reserved.